Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | $1.2M | $4.4M | $4.0M | $46.7M | $9.3M | $1.3M |
| Cost of revenue | $823.0K | $2.0M | $55.0M | $82.9M | $88.6M | $14.4M | $15.7M | $7.6M |
| Gross profit | −$823.0K | −$2.0M | −$53.8M | −$78.5M | −$84.6M | $32.3M | −$6.4M | −$6.3M |
| Gross margin | — | — | -4530.6% | -1799.1% | -2095.8% | 69.2% | -69.3% | -470.3% |
| R&D | $13.9M | $35.7M | $55.0M | $82.9M | $88.6M | $97.5M | $111.4M | $127.2M |
| Operating income | −$19.0M | −$41.8M | −$65.6M | −$97.9M | −$106.0M | −$75.2M | −$120.4M | −$154.6M |
| EBITDA | −$18.2M | −$39.8M | −$61.6M | −$93.2M | −$98.7M | −$68.7M | −$111.9M | −$126.9M |
| Net income | −$18.8M | −$41.4M | −$64.8M | −$90.9M | −$104.6M | −$75.0M | −$113.1M | −$138.5M |
| Net margin | — | — | -5457.0% | -2083.1% | -2591.3% | -160.4% | -1220.5% | -10405.0% |
| EPS (diluted) | -0.93 | -2.06 | -7.26 | -2.71 | -2.77 | -0.95 | -1.24 | -1.20 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $35M | $-0.32 | $-0.46–$-0.18 | 2 |
| 2027 | $23M | $-0.98 | $-0.98–$-0.98 | 1 |
| 2028 | $122M | $-0.65 | $-0.65–$-0.65 | 1 |
Forward consensus · source: Financial Modeling Prep
No one on the platform currently holds GRTS.
No tracked institution reports a position in GRTS as of their last filing.
No one on the platform has traded GRTS yet.
| $4M |
| — |
| IDRAIdera Pharmaceuticals, Inc. | $0.42 | -23.04% | $0 | — |
| ONCOOnconetix, Inc. | $0.95 | -2.27% | $318764 | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 1.0× sales vs its 34.2× historical median P/S.
Fair value ≈ $1.07 · price $0.03 today
Fair-value line = the stock's median historical P/S × sales per share. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.
When we see a stock like this, we know how many damaged investors are out there. Believe it or not, there’s some good news. $GRTS investors you might be surprised, but you actually have a chance to recover your losses. Don’t miss it: https://11th.com/cases/gritstone-investor-settlement
View on StockTwits ↗Gritstone Bio ($GRTS) Settlement Update The case has moved forward. The settlement agreement has now been submitted to the court for approval. Investors can already review the settlement details and submit a claim while the approval process moves forward. https://11th.com/cases/gritstone-investor-settlement We'll keep an eye on future updates and key dates.
View on StockTwits ↗Don't forget that there is also an important settlement to watch for $GRTS We have every detail, including how investors can get paid: https://11th.com/cases/gritstone-investor-settlement
View on StockTwits ↗$GRTS Second time the scumbag Andrew Allen has been sued.
View on StockTwits ↗$GRTS investors — there’s no hidden secret here. Just one thing you really need to know. Here’s how to handle your losses. More importantly, how to either recover them or risk losing even more: https://11th.com/cases/gritstone-investor-settlement
View on StockTwits ↗$GRTS What happened to @nickpd lmfaooooo @biotechwinners lmfaoooo @r8 lmfaooooooo
View on StockTwits ↗$ACXP Don't Invest or Trade in this Stock, Previous Year It Trade As $GRTS and I got Scamed by this Company... It's a nasdaq Supported Scammer.
View on StockTwits ↗But honestly better here than in dead $GRTS where infamous Captain Nick lost everything and disappeared from the radars for good 😂
View on StockTwits ↗$GRTS @nickpd I told you this company was fake. Loser!!!!
View on StockTwits ↗Next-gen vaccine delivery about to have its moment: $BIOV leading with no-oil DPX (RSV Phase1 93% response, mRNA carrier incoming) $VBIV VBI-2900 series $DVAX CpG dominance $GRTS het-rec platform One big readout and the whole group rerates. Eyes on McMaster update 👀
View on StockTwits ↗Small-cap immuno-oncology is waking up FAST: $BIOV (DPX + survivin, insider cash, tiny float) $IMV old believers know the tech $CADL (NeoTCR) $GRTS (Gritstone gorilla) $PASG (precision) When one rips they all get discovered again. Loading season 🚀
View on StockTwits ↗$GRTS what happened to this company? What happened to the assets?
View on StockTwits ↗Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.